Clinical Trials Logo

Renal Transplant Patients clinical trials

View clinical trials related to Renal Transplant Patients.

Filter by:
  • None
  • Page 1

NCT ID: NCT03270462 Completed - Clinical trials for Renal Transplant Patients

CNS Study of Patients Switching From Tacrolimus to Envarsus

Start date: December 1, 2017
Phase: Phase 4
Study type: Interventional

This is a pilot study documenting the neurotoxic side effects including tremors in patients with a stable graft who are receiving Tacrolimus following kidney transplantation. A standardized questionnaire will be used to document these symptoms.

NCT ID: NCT00913796 Completed - Metabolic Acidosis Clinical Trials

Metabolic Acidosis in Renal Transplant Patients

MART
Start date: December 2007
Phase: Phase 2
Study type: Interventional

Acidosis (accumulation of acid in the body) may be an underrecognized problem in patients after renal transplantation. It may have consequences on physical performance due to negative effects on bone and muscle metabolism. Therefore, the purpose of this study is 1. to determine the status of physical capacity and bone structure in renal transplant patients with metabolic acidosis 2. to study the effect of substituting base equivalents (citrate) on acid/base status of renal transplant patients with acidosis 3. to compare the status of physical capacity and bone structure in renal transplant patients with metabolic acidosis before and after substitution with citrate

NCT ID: NCT00733733 Recruiting - Clinical trials for Renal Transplant Patients

Anti-T-Lymphocyte Globulin (ATG) in Renal Transplantation of Kidneys With a Non-Heart-Beating (NHB) Donor

ATG
Start date: January 2008
Phase: Phase 3
Study type: Interventional

One of the greatest problems in renal transplantation is the shortage of donor kidneys. Kidneys of non-heart-beating donors (NHB) are a possible solution, but transplantation is accompanied with a high percentage of acute renal failure, caused by ischemia-reperfusion injury. The increased ischemia-reperfusion injury results in an increased immune activation, which can lead to more injury of the kidney and additional acute rejections. The hypothesis of this trial is that ischemia-reperfusion injury can be diminished by ATG. ATG could have additional favourable effects. To investigate this half of the patients is treated with additional ATG to the standard immunosuppressive treatment. Calcineurin inhibitors are not diminished during the first days after transplantation to investigate whether ATG has special effects on ischemia-reperfusion injury.